On the structural basis and design guidelines for type II topoisomerase-targeting anticancer drugs
about
Novel DNA topoisomerase IIα inhibitors from combined ligand- and structure-based virtual screeningExploring the active site of the Streptococcus pneumoniae topoisomerase IV-DNA cleavage complex with novel 7,8-bridged fluoroquinolonesRecovery of the poisoned topoisomerase II for DNA religation: coordinated motion of the cleavage core revealed with the microsecond atomistic simulation.Structure-based design, synthesis and biological testing of etoposide analog epipodophyllotoxin-N-mustard hybrid compounds designed to covalently bind to topoisomerase II and DNAFitness profiling links topoisomerase II regulation of centromeric integrity to doxorubicin resistance in fission yeastStructure-based design, synthesis and biological testing of piperazine-linked bis-epipodophyllotoxin etoposide analogsDNA-Dye-Conjugates: Conformations and Spectra of Fluorescence Probes.Mechanisms of Action and Reduced Cardiotoxicity of Pixantrone; a Topoisomerase II Targeting Agent with Cellular Selectivity for the Topoisomerase IIα Isoform.A "Double-Edged" Scaffold: Antitumor Power within the Antibacterial Quinolone.Phenanthriplatin Acts As a Covalent Poison of Topoisomerase II Cleavage Complexes.Mitoxantrone, More than Just Another Topoisomerase II Poison.Review structure- and dynamics-based computational design of anticancer drugs.Natural variation in a single amino acid substitution underlies physiological responses to topoisomerase II poisons.Preparation, characterization and evaluation of (186) Re-idarubicin: a novel agent for diagnosis and treatment of hepatocellular carcinoma.Anthraquinones As Pharmacological Tools and Drugs.Pathways of cardiac toxicity: comparison between chemotherapeutic drugs doxorubicin and mitoxantrone.Structure of a quinolone-stabilized cleavage complex of topoisomerase IV from Klebsiella pneumoniae and comparison with a related Streptococcus pneumoniae complex.Structural basis of DNA gyrase inhibition by antibacterial QPT-1, anticancer drug etoposide and moxifloxacin.An optimized polyamine moiety boosts the potency of human type II topoisomerase poisons as quantified by comparative analysis centered on the clinical candidate F14512.Mode of action of DNA-competitive small molecule inhibitors of tyrosyl DNA phosphodiesterase 2.Roles of the C-terminal domains of topoisomerase IIα and topoisomerase IIβ in regulation of the decatenation checkpoint.New insights into the mechanism of action of pyrazolo[1,2-a]benzo[1,2,3,4]tetrazin-3-one derivatives endowed with anticancer potential.Producing irreversible topoisomerase II-mediated DNA breaks by site-specific Pt(II)-methionine coordination chemistry.Topoisomerases as anticancer targets.A new class of antibacterials, the imidazopyrazinones, reveal structural transitions involved in DNA gyrase poisoning and mechanisms of resistance.Drug-induced conformational population shifts in topoisomerase-DNA ternary complexes.Exploring the Effects of Glycosylation and Etherification of the Side Chains of the Anticancer Drug Mitoxantrone.Residues contributing to drug transport by ABCG2 are localised to multiple drug-binding pockets.An overview of recent advances in duplex DNA recognition by small molecules.Trapping of the transport-segment DNA by the ATPase domains of a type II topoisomerase.Binding mechanism of anti-cancer chemotherapeutic drug mitoxantrone to DNA characterized by magnetic tweezers.Increasing the distance between two monomers of topoisomerase IIβ under the action of antitumor agent 4β-sulfur-(benzimidazole) 4'-demethylepipodophyllotoxinThe structure of the deubiquitinase USP15 reveals a misaligned catalytic triad and an open ubiquitin-binding channelDNA damage and apoptosis induced by a potent orally podophyllotoxin derivative in breast cancerStructural insights into the gating of DNA passage by the topoisomerase II DNA-gatenZ,(n + 4)Z-Dienoic fatty acids: a new method for the synthesis and inhibitory action on topoisomerase I and IIα
P2860
Q28542613-3B794012-046B-4837-96E2-5949FA518EDEQ28828291-60D5EEB2-C7EA-4B23-A5B0-CC6E4A0B4D5DQ30661486-9D00D23B-1547-48CD-A02C-8AA616E3B355Q34623523-B9E6690F-F2EE-40F8-ACF7-A75CA57FAA33Q35070152-0ED01BE4-8C4D-426A-B7EA-D2B3D83E268EQ35706214-E3043FD1-7A95-4ADE-9835-C9843F2DFCAAQ36088347-96DD3685-F921-4D80-86A5-37FA6E7CE7B4Q36559677-E3538EBA-2A70-4F34-A5D8-9187A1D5892EQ37204002-EDA18149-2E62-45F1-8344-2DBF0043E648Q37596167-97403290-A68A-4B3A-A169-5BE3E741BB79Q38569206-A2961714-AA8A-4CC8-8C5B-65C924FB3D41Q38589320-ADA4826D-DD1B-417E-A4D5-F99AF1F0F51EQ38682376-9A15038B-1A9F-4F95-85D8-F441FB5B2546Q38806912-6512A56E-0CAF-40FD-A270-0F7B379627BEQ38816745-65F22B98-62D8-4816-B81A-D600DC1A0C34Q38876257-0E571C65-8A61-4404-902F-740D45D43FBCQ39911518-95D72FD2-0E8A-4026-BB88-A61A7BAC4A01Q40239631-5A4777C6-554F-47D8-B924-BAAF6E9CEB8CQ40669367-5063F1C7-7F33-4443-9838-D964B282A840Q42181420-4A84B54B-6F7E-4DBB-8D12-655009C66C77Q42234159-572F4056-ECB0-4F5D-8AB5-8F559114998AQ47677627-218F5626-159A-4830-B068-F5FA7E531A93Q47699480-7FE523E1-D644-4F52-8465-8536403F292AQ49832269-6CDF18D6-E859-4658-8B42-676A50686FA5Q52355825-9EA84933-6C37-4A45-9E8F-3141EBB00DA3Q53044182-FB9001C9-61CD-4AE7-AE28-06EF61E9E6C8Q53397800-DC13401F-612C-4227-A573-C858783962C6Q53694857-0F74C129-39D5-4A15-90C0-DD4F922210CFQ55476273-9F75F877-765A-4558-A6E9-CE0B349CFB06Q55518315-E9270B02-65FE-45F7-A444-35E74DE20780Q55633988-0BF8618F-C797-4983-AB72-C307A4641C48Q57296142-F77A9E92-3A6B-49EC-A00B-B95BEBC9C2CBQ58690927-49D88443-DD81-40F0-B220-1581F39EB3CEQ58768143-AEEE069B-4DCA-4021-81BF-B34B80C123E5Q58799715-49540191-3CCB-4C67-891E-A477987038F4Q59237285-3455E000-C48A-498D-849D-1E0816B7BF32
P2860
On the structural basis and design guidelines for type II topoisomerase-targeting anticancer drugs
description
2013 nî lūn-bûn
@nan
2013 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
On the structural basis and de ...... ase-targeting anticancer drugs
@ast
On the structural basis and de ...... ase-targeting anticancer drugs
@en
On the structural basis and de ...... ase-targeting anticancer drugs
@nl
type
label
On the structural basis and de ...... ase-targeting anticancer drugs
@ast
On the structural basis and de ...... ase-targeting anticancer drugs
@en
On the structural basis and de ...... ase-targeting anticancer drugs
@nl
prefLabel
On the structural basis and de ...... ase-targeting anticancer drugs
@ast
On the structural basis and de ...... ase-targeting anticancer drugs
@en
On the structural basis and de ...... ase-targeting anticancer drugs
@nl
P2093
P2860
P3181
P356
P1476
On the structural basis and de ...... ase-targeting anticancer drugs
@en
P2093
Tsai-Kun Li
Yi-Ching Li
Ying-Ren Wang
P2860
P304
10630-10640
P3181
P356
10.1093/NAR/GKT828
P407
P577
2013-12-01T00:00:00Z